江中药业股份有限公司 2023 年第一次临时股东大会会议材料 二〇二三年九月 江中药业股份有限公司 2023 年第一次临时股东大会会议材料 股票简称：江中药业 股票代码：600750 南 昌 江中药业股份有限公司 2023 年第一次临时股东大会会议材料 议案目录 2 江中药业股份有限公司 2023 年第一次临时股东大会会议材料 江中药业股份有限公司 股东大会会议须知 为了维护全体股东的合法权益、依法行使股东职权，确保股东大会的 正常秩序和议事效率，根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司股东大会规则》、《公司章程》及《公司股东大 会议事规则》，特制订本须知。 一、股东大会设秘书处，具体负责大会有关程序方面的事宜。 二、会议期间全体出席会议人员应以维护股东合法权益、确保大会正 常秩序、提高议事效率为原则，认真履行法定职责。 | | | 三、为保证股东大会的严肃性和正常秩序，除依法出席会议的公司股 东（或其授权代表）、董事、监事、董事会秘书、高级管理人员、聘请的 律师和董事会邀请参会的人员外，公司有权依法拒绝其他人士入场。 四、出席会议的股东（或其授权代表）必须在会议召开前十分钟向大 ...

Financial Performance - The company reported a half-year revenue of RMB 1.2 billion, representing a 15% increase compared to the same period last year[30]. - The net profit for the first half of 2023 was RMB 300 million, up 20% year-on-year[30]. - The company's operating revenue for the first half of 2023 reached ¥2,297,549,382.03, representing a 20.87% increase compared to the same period last year[52]. - Net profit attributable to shareholders of the listed company was ¥447,001,834.46, an increase of 13.95% year-on-year[52]. - The net profit after deducting non-recurring gains and losses was ¥414,012,620.10, reflecting a 16.04% increase compared to the previous year[52]. - The basic earnings per share for the first half of 2023 was ¥0.70, up 12.90% from ¥0.62 in the same period last year[52]. - The company achieved a net profit attributable to the parent company of 447 million yuan, an increase of 55 million yuan year-on-year, representing a growth of 13.95%[101]. - The company's operating revenue for the reporting period was 2.298 billion yuan, an increase of 397 million yuan year-on-year, with a growth rate of 20.87%[103]. - The revenue from the health and other businesses reached 285 million yuan, showing a significant year-on-year growth of 59.47%[106]. User Growth and Market Expansion - User data indicates a growth of 25% in active users, reaching 5 million by the end of June 2023[30]. - The company plans to launch two new products in Q3 2023, aiming to capture an additional 10% market share[30]. - The company is expanding its market presence in Southeast Asia, targeting a revenue contribution of 5% from this region by the end of 2024[30]. - A strategic acquisition of a local competitor is expected to be finalized by Q4 2023, which will enhance the company's product offerings[30]. - The management has indicated a positive outlook for future performance, supported by strategic initiatives and market expansion plans[57]. Research and Development - Research and development expenses increased by 30%, totaling RMB 150 million, reflecting the company's commitment to innovation[30]. - The company is committed to ongoing research and development in new products and technologies to enhance market competitiveness[57]. - The company's R&D intensity for 2022 was 3.89%, exceeding the required minimum of 2.96%[176]. Sustainability and Environmental Compliance - The management highlighted a focus on sustainability initiatives, aiming to reduce operational costs by 10% through energy efficiency measures[30]. - The company has implemented a comprehensive wastewater treatment process at the Luoting base, with a design capacity of 800 tons per day, utilizing biochemical treatment methods[168]. - The company’s wastewater treatment facilities are operating normally, with pollutant discharge concentrations meeting or exceeding national and local environmental protection standards[168]. - The company has established an online monitoring system for wastewater discharge, ensuring real-time tracking of key indicators such as COD, ammonia nitrogen, pH, flow rate, and water temperature[168]. - The company has made donations to strengthen the infrastructure of the local community, enhancing grassroots party organization cohesion[199]. - The company has supported local agricultural development by helping to sell over 500 pounds of blueberries from the village[200]. - The company has provided direct drinking water equipment to improve the living conditions in the village[200]. Financial Management and Assets - The company reported a significant improvement in cash flow, with a cash position of RMB 500 million, up 40% from the previous year[30]. - The company's cash and cash equivalents at the end of the period amounted to 2.627 billion yuan, an increase of 1.256 billion yuan, representing a growth of 91.59%[116]. - The company’s online business revenue accounted for over 10% of total sales during the reporting period[111]. - The company has established a mature channel coverage and terminal management capability, covering 200,000 terminal pharmacies and collaborating closely with 3,000 commercial partners[102]. Industry Trends and Challenges - The pharmaceutical industry is undergoing a restructuring due to the implementation of the eighth batch of national drug procurement and the unification of the national medical insurance catalog, leading to a more standardized and efficient use of medical insurance funds[59]. - The overall growth of the pharmaceutical manufacturing industry faced pressure, with the value added of the pharmaceutical manufacturing industry declining by 4.9% year-on-year in the first half of 2023[59]. - The company anticipates potential revenue impacts from the inclusion of its product in the national drug procurement list, which may affect future earnings[124]. - The company plans to expand its procurement channels for traditional Chinese medicine materials to ensure supply chain security amid price fluctuations[124]. Corporate Governance and Risk Management - The company did not face any significant risks that could materially affect its operations during the reporting period[44]. - The company will closely monitor national policies and industry trends to adjust its business strategies and enhance core competitiveness[124]. - The company has not faced any environmental pollution incidents or administrative penalties during the reporting period[177].

证券代码：600750 证券简称：江中药业 公告编号:2023-025 江中药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 江中药业股份有限公司（以下简称"公司"）将于 2023 年 8 月 24 日发布公 司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度 经营成果和财务状况，公司计划于 2023 年 8 月 29 日下午 15:00-16:30 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2023 年半年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （网址：http://roadshow.sseinfo.com/） 会议召开时间：2023 年 8 月 29 日(星期二)下午 15:00-16:30 会议召开地点：上海证 ...

江中药业股份有限公司 关于参加沪市主板生物医药行业上市公司2022年年报 集体业绩说明会暨2023年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 江中药业股份有限公司（以下简称"公司"）已于2023年3月25日发布了公司 2022年年度报告，于2023年4月27日发布了公司2023年第一季度报告，为便于广大 投资者更全面深入地了解公司2022年度及2023年第一季度经营成果、财务状况，同 时更加充分地向投资者展示生物医药行业发展情况，公司计划于2023年5月12日下 午13:00-14:30参加沪市主板生物医药行业上市公司2022年年报集体业绩说明会，就 投资者关心的问题进行交流。 证券代码：600750 证券简称：江中药业 公告编号：2023-019 具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍 关注问题进行回答 。 二、说明会召开的时间、地点及活动日程 三、参加人员 董事长：刘为权先生 总经理：肖文斌先生 财务总监：李小俊先生 董事会秘书：田永静女 ...

Financial Position - The total assets of the company amount to 6,316,949,481.06 yuan, an increase from 6,243,659,088.84 yuan in the previous period[10]. - The company reported a total of 1,473,621,799.63 yuan in current liabilities, a decrease from 1,657,669,253.49 yuan in the previous period[10]. - The company has a total of 138.5 million yuan in other non-current financial assets[10]. - The total liabilities decreased to ¥1,561,109,382.72 from ¥1,748,281,711.63, indicating improved financial stability[50]. - Equity attributable to shareholders increased by 6.25% to ¥4,134,244,495.15 from ¥3,890,966,277.28[37]. Cash Flow - The company's cash and cash equivalents at the end of the period are 492,765,197.35 yuan, down from 550,324,166.65 yuan at the beginning of the period, resulting in a net decrease of 57,558,969.30 yuan[15]. - Operating cash inflow totaled $1,239,030,198.30, an increase from $751,780,919.26 in the previous period[71]. - Operating cash outflow amounted to $1,177,138,767.46, compared to $771,340,336.36 previously, resulting in a net cash flow from operating activities of $61,891,430.84, up from a negative $19,559,417.10[71]. - Investment cash inflow was $763,779,065.02, down from $864,376,241.00 in the prior period[71]. - Investment cash outflow reached $883,229,465.16, compared to $679,966,641.72 previously, leading to a net cash flow from investing activities of -$119,450,400.14, down from $184,409,599.28[71]. - The company received tax refunds amounting to $21,567,303.42[71]. - Cash received from other operating activities was $39,269,633.66, compared to $19,211,152.76 previously[71]. - Total cash paid for taxes was $157,140,068.85, up from $74,980,014.68[71]. Revenue and Profitability - The company's operating revenue for Q1 2023 reached ¥1,316,378,726.66, representing a year-on-year increase of 41.44%[20]. - The net profit attributable to shareholders of the listed company was ¥240,831,060.77, up 31.10% compared to the same period last year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥224,783,546.46, reflecting a 29.61% increase year-on-year[20]. - The basic earnings per share for the period was ¥0.38, which is a 31.03% increase from the previous year[20]. - The gross profit margin for over-the-counter drugs was 72.80%, an increase of 3.41 percentage points compared to the same period last year[24]. - The revenue from the health products and others segment surged by 184.66% year-on-year, although the gross profit margin decreased to 33.15%[24]. - Revenue from the East China region increased by 83.65% year-on-year, amounting to ¥459,336,359.19[24]. - The gross margin for the pharmaceutical industry was 67.97%, a decrease of 0.99 percentage points year-on-year[37]. - The company reported a decrease in the gross margin for health products and others, primarily due to changes in product revenue structure[39]. Expenses and Investments - The company's total operating costs for Q1 2023 were CNY 1,034,301,889.35, compared to CNY 721,704,291.98 in Q1 2022, marking an increase of around 43.4%[70]. - Research and development expenses for Q1 2023 amounted to CNY 26,642,289.45, slightly down from CNY 27,972,879.52 in Q1 2022[70]. - The company's sales expenses for Q1 2023 were CNY 531,495,354.11, up from CNY 353,212,883.66 in Q1 2022, indicating an increase of approximately 50.6%[70]. - The tax expenses for Q1 2023 were CNY 46,598,116.68, compared to CNY 36,263,791.67 in Q1 2022, reflecting an increase of about 28.6%[70]. - The investment income for Q1 2023 showed a loss of CNY 350,858.42, compared to a gain of CNY 1,189,302.97 in Q1 2022[70]. Legal and Other Matters - As of the reporting period, the company has a remaining overdue principal of 6.75 million yuan from entrusted loans to Changrong Automobile, with legal actions ongoing[4]. - The company has initiated a lawsuit against Changrong Automobile and related guarantors to recover overdue loans[4]. - The company has plans for future entrusted financial management, indicating ongoing investment strategies[5]. - The company has a total of 3,100,000 shares held through margin accounts by its representative, Luo Jun[3]. - The total number of ordinary shareholders at the end of the reporting period was 35,551[27].

Financial Performance - The company's operating revenue for 2022 was CNY 3,811,641,510.59, representing a 32.63% increase compared to CNY 2,873,974,462.18 in 2021[9] - The net profit attributable to shareholders for 2022 was CNY 596,058,708.67, up 17.87% from CNY 505,687,248.49 in the previous year[9] - The net profit after deducting non-recurring gains and losses was CNY 506,520,866.82, reflecting a 19.42% increase from CNY 424,156,470.17 in 2021[9] - The net cash flow from operating activities for 2022 was CNY 1,015,989,416.27, a 10.79% increase compared to CNY 917,037,660.75 in 2021[9] - The company's total assets at the end of 2022 were CNY 6,243,659,088.84, which is a 4.10% increase from CNY 5,997,600,248.38 at the end of 2021[9] - The basic earnings per share for 2022 was CNY 0.94, representing a 17.50% increase compared to CNY 0.80 in 2021[37] - The diluted earnings per share for 2022 was also CNY 0.94, consistent with the basic earnings per share[37] - The gross profit margin for the main business was 64.93%, an increase of 0.52 percentage points compared to the same period last year[78] Dividends and Shareholder Returns - The proposed cash dividend for 2022 is CNY 6.5 per 10 shares, which would total approximately CNY 40,920.68 million, accounting for 68.65% of the net profit attributable to shareholders[15] - The total cash dividend for 2022, including the distribution from the first three quarters, is estimated to be CNY 72,399.78 million, exceeding 121.46% of the net profit attributable to shareholders[15] - The company maintained a cumulative cash dividend ratio of 50% of the net profit attributable to the parent company since its restructuring listing, emphasizing shareholder returns[62] Operational Highlights - The company completed a share buyback of 33,000 restricted shares in February 2023, which will affect the total number of shares for the dividend distribution[15] - There were no significant risks identified that could materially impact the company's operations during the reporting period[19] - The company achieved operating revenue of 3.812 billion yuan in 2022, a year-on-year increase of 32.63%[45] - The company’s total share capital decreased from 630,000,000 shares at the beginning of the year to 629,581,958 shares at the end of the year due to the cancellation of treasury shares[37] Segment Performance - The non-prescription drug segment generated revenue of 2.618 billion yuan, up 21.31% year-on-year, with core products showing significant growth[52] - The health business reported revenue of 409 million yuan, marking a substantial increase of 66.99% year-on-year[50] - The prescription drug segment saw revenue of 745 million yuan, a remarkable growth of 64.40% year-on-year, largely due to the integration of Haise Pharmaceutical[55] Research and Development - The company introduced 1 generic drug and received 4 supplementary approvals for existing products during the reporting period[56] - The company increased R&D investment and completed 2 special medical products on-site verification during the reporting period[136] - The company’s R&D expenses amounted to CNY 99.97 million, reflecting a year-on-year increase of 13.83%[75] - The company employed 239 R&D personnel, making up 5.9% of the total workforce[102] Market Trends and Challenges - The company anticipates challenges from global economic downturns and ongoing price reductions in generic drugs, necessitating operational innovations[113] - The OTC market is experiencing increased demand due to a shift towards preventive healthcare, with a growing focus on immune enhancement products[114] - The health products market is entering a "golden period" of rapid growth, driven by rising consumer awareness and demand for self-care[117] - The traditional Chinese medicine market is expected to benefit from supportive policies, with a focus on high-quality development and innovation[114] Environmental and Social Responsibility - The group has implemented a wastewater treatment facility with a capacity of 20,000 m³/h, ensuring compliance with discharge standards[166] - The group has adopted natural gas as a clean energy source across all production bases, with emissions of SO2 and nitrogen oxides meeting standards[167] - Jiangzhong Pharmaceutical invested CNY 2.0808 million in social assistance projects, including CNY 1.45 million in funds and CNY 630,800 in material donations[174] - The company has committed to maintaining operational independence and protecting the rights of shareholders, ensuring no misuse of its controlling position[177] Strategic Initiatives - The company is expected to officially launch a new "smart, green, and economical" manufacturing park by the end of 2023[59] - The company has established a robust organizational structure to support its "14th Five-Year Plan" strategy, focusing on talent development and effective execution[61] - The company is actively enhancing its investor relations management tools and improving ESG information disclosure to create a more transparent corporate image[62]

Financial Performance - The company's operating revenue for Q3 2022 was ¥973,492,830.29, representing a year-over-year increase of 44.95%[7] - The net profit attributable to shareholders for the same period was ¥112,645,005.35, showing a decrease of 22.46% compared to the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥93,205,288.58, down 25.69% year-over-year[7] - The company reported a basic earnings per share of ¥0.18, a decrease of 21.74% compared to the same period last year[11] - Total operating revenue for the first three quarters of 2022 reached ¥2,874,367,383.35, a significant increase from ¥1,937,836,872.68 in the same period of 2021, representing a growth of approximately 48.7%[65] - Net profit for the third quarter of 2022 was ¥538,381,354.78, compared to ¥466,437,225.31 in the same quarter of 2021, reflecting a growth of approximately 15.4%[69] - The profit attributable to shareholders of the parent company for the third quarter of 2022 was ¥504,936,397.50, an increase from ¥451,831,116.71 in the previous year, marking a rise of about 11.8%[69] - The company reported a total profit of ¥642,082,256.09 for the third quarter of 2022, compared to ¥556,267,148.77 in the same quarter of 2021, representing an increase of about 15.4%[69] - The total comprehensive income for the period was CNY 538,381,354.78, an increase from CNY 466,437,225.31 in the previous year, representing a growth of approximately 15.4%[71] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,153,454,605.92, an increase of 2.60% from the end of the previous year[11] - The total liabilities as of the reporting date were ¥1,456,936,411.58, up from ¥1,415,111,640.54, indicating a rise of about 2.9%[62] - The total equity attributable to shareholders of the parent company was ¥4,106,814,784.16, compared to ¥4,003,034,097.91 in the previous year, reflecting an increase of approximately 2.6%[62] - The company's cash and cash equivalents increased to CNY 1,204,958,052.65 from CNY 1,046,084,852.69 year-over-year[57] - The total current assets reached CNY 4,073,306,960.02, slightly up from CNY 4,064,479,153.32 in the previous year[57] - The company's non-current assets totaled CNY 2,080,147,645.90, compared to CNY 1,933,121,095.06 at the end of 2021[60] - The total liabilities included accounts payable of CNY 174,210,393.33, which increased from CNY 163,094,814.55 year-over-year[60] - The company reported a significant increase in other payables, which reached CNY 797,242,140.95, up from CNY 625,563,238.17[60] Revenue Breakdown - The gross profit margin for the pharmaceutical industry segment was 66.80%, an increase of 0.56 percentage points year-over-year[18] - The revenue from non-prescription drugs was ¥2,008,238,596.27, with a year-over-year increase of 30.12%[18] - The company experienced a significant revenue increase of 134.16% in the prescription drug category, totaling ¥557,556,853.45[18] - The revenue from the North China region was ¥675,838,153.16, reflecting a year-over-year increase of 76.47%[17] - The company attributed the revenue growth primarily to the acquisition of Hais Pharmaceutical, which expanded the scope of consolidation[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,203[24] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, accounting for 43.06% of the total shares[24] - The second-largest shareholder, Hong Kong Central Clearing Limited, holds 21,222,397 shares, representing 3.37%[24] Cash Flow and Investments - The net cash flow from operating activities was CNY 454,923,017.17, slightly down from CNY 462,330,380.86 in the same period last year[75] - Cash inflow from operating activities totaled CNY 2,811,749,322.38, compared to CNY 2,011,623,620.03 in the previous year, indicating a growth of about 39.8%[75] - The net cash flow from investing activities was CNY 199,336,385.74, a significant improvement from a negative CNY 754,158,348.62 in the previous year[75] - The company paid CNY 418,171,159.55 in dividends and interest, compared to CNY 176,028,635.25 in the previous year, reflecting an increase of approximately 137.0%[75] - The net increase in cash and cash equivalents for the period was CNY 237,358,072.28, contrasting with a decrease of CNY 541,137,940.43 in the previous year[77] Research and Development - Research and development expenses for the first three quarters of 2022 totaled ¥72,884,666.04, compared to ¥47,762,731.83 in 2021, showing an increase of approximately 52.6%[65] Share Capital Changes - The company completed the cancellation of 274,000 shares from an incentive plan, reducing the total share capital from 629,912,000 to 629,638,000 shares[30] - The company adjusted the purpose of 56,042 shares in the repurchase account to be used for capital reduction, further reducing the total share capital to 629,581,958 shares[30]

Financial Performance - The company reported a total revenue of RMB X million for the first half of 2022, representing a Y% increase compared to the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was RMB A million, reflecting a B% growth year-on-year[19]. - The company's operating revenue for the first half of 2022 reached ¥1,900,874,553.06, representing a 50.12% increase compared to the same period last year[21]. - Net profit attributable to shareholders was ¥392,291,392.15, up 27.96% year-on-year[21]. - The net cash flow from operating activities increased by 62.11% to ¥478,885,030.43[21]. - Basic earnings per share rose to ¥0.62, a 26.53% increase from ¥0.49 in the previous year[21]. - The company's total revenue for the reporting period was 1.901 billion yuan, an increase of 635 million yuan, reflecting a year-on-year growth of 50.12%[39]. - The company achieved a net profit attributable to the parent company of 392 million yuan, an increase of 86 million yuan, representing a growth of 27.96% compared to the same period last year[33]. - Total operating revenue for the first half of 2022 reached ¥1,900,874,553.06, a 50% increase from ¥1,266,215,659.65 in the same period of 2021[181]. - The total profit for the period was CNY 493,251,746.39, representing a 33.0% increase from CNY 371,284,194.32 in the prior year[186]. Market Engagement and Expansion - User data showed an increase in active users by C% during the reporting period, indicating strong market engagement[19]. - The company has set a revenue target of RMB D million for the full year 2022, which represents an E% increase from the previous year[19]. - The company is expanding its market presence in regions G and H, aiming for a market share increase of I% by the end of 2022[19]. - The company is focusing on expanding its online sales channels, enhancing its presence on platforms like Tmall, JD.com, and Pinduoduo[42]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[186]. Innovation and Research - New product launches contributed to F% of total sales in the first half of 2022, showcasing the effectiveness of the company's innovation strategy[19]. - Research and development expenses increased by J% compared to the previous year, highlighting the company's commitment to innovation[19]. - The company is committed to integrating traditional Chinese medicine with modern scientific research to enhance its product offerings and market competitiveness[38]. - The company is actively developing new products in the gastrointestinal and probiotic categories, leveraging its brand influence in the digestive health sector[42]. - The company initiated a joint research project for a new drug candidate targeting Alzheimer's disease, enhancing its R&D pipeline[45]. Financial Management and Investments - The company has been actively managing its investment portfolio to optimize returns while maintaining liquidity[87]. - The company plans to continue expanding its investment strategies in the upcoming quarters to enhance overall performance[87]. - The total amount of entrusted financial management reached 50,000,000.00 with an annualized return rate of 4.26% for the product managed by China Merchants Bank, Nanchang Aixi Lake Branch[72]. - The overall performance of entrusted financial management products indicates a consistent return across various banks, with amounts typically around 50,000,000.00 to 100,000,000.00 and annualized return rates ranging from 3.09% to 4.53%[72][75][76][77][78]. Environmental Compliance and Initiatives - The company has not experienced any environmental pollution incidents and has not received any administrative penalties related to environmental protection during the reporting period[100]. - The company won the 11th China Environmental Excellence Award in 2022, recognizing its efforts in environmental protection[100]. - The company has established two comprehensive wastewater treatment stations to handle all production and domestic wastewater from its facilities[100]. - The company has implemented online monitoring stations at all wastewater discharge outlets to ensure compliance with environmental regulations, including real-time monitoring of chemical oxygen demand, ammonia nitrogen, pH, flow rate, and water temperature[115]. - The company has actively promoted distributed photovoltaic projects to increase the share of clean energy in its operations, supporting national carbon neutrality goals[130]. Community Engagement and Social Responsibility - The company invested a total of 920,000 yuan in poverty alleviation and rural revitalization efforts during the reporting period[132]. - The company donated 400,000 yuan for the development of local industries, specifically targeting the cultivation of Ganoderma, Chrysanthemum, and bamboo[134]. - The company aims to complete the construction of a care center for left-behind children, providing a supportive environment[134]. - The company emphasizes the importance of party leadership in driving rural social governance and community participation[134]. Shareholder and Corporate Governance - The company reported a total share capital of 630,000,000 shares, which decreased to 629,912,000 shares after the cancellation of 88,000 shares[150]. - The integrity status of the company and its controlling shareholders is good, with no unfulfilled court judgments or significant debts due[143]. - The company has made commitments to minimize and regulate related party transactions with Jiangzhong Pharmaceutical[140]. - The company has no significant litigation or arbitration matters during the reporting period[143].

Financial Performance - The company's operating revenue for Q1 2022 was ¥930,726,704.79, representing a year-on-year increase of 37.38%[5] - Net profit attributable to shareholders was ¥183,697,243.65, reflecting a growth of 15.28% compared to the same period last year[5] - Total operating revenue for Q1 2022 reached ¥930.73 million, a 37.4% increase from ¥677.47 million in Q1 2021[48] - Net profit for Q1 2022 was ¥193.60 million, representing a 19.4% increase compared to ¥162.12 million in Q1 2021[48] - Earnings per share for Q1 2022 were ¥0.29, compared to ¥0.25 in Q1 2021[50] - Cash received from sales of goods and services in Q1 2022 was ¥732.57 million, an increase from ¥549.86 million in Q1 2021[50] Cash Flow - The net cash flow from operating activities was -¥19,559,417.10, a decrease of 130.85% year-on-year[5] - The net cash flow from operating activities decreased to -$19.56 million from $63.40 million year-over-year, indicating a significant decline in operational performance[54] - Cash received from operating activities totaled $751.78 million, an increase from $566.33 million, suggesting improved revenue generation[54] - Cash inflow from investment activities totaled $864.38 million, down from $1,076.48 million, reflecting a decrease in investment recovery[54] - Cash outflow for investment activities was $679.97 million, compared to $1,130.51 million in the previous period, showing a reduction in capital expenditures[54] - The net cash flow from financing activities was -$299,643.48, indicating that the company had a net outflow in this category[56] - The ending cash and cash equivalents balance was $353.16 million, down from $867.00 million, highlighting a significant decrease in liquidity[56] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to ¥6,093,177,254.01, an increase of 1.59% from the end of the previous year[7] - The total assets of the company reached approximately ¥6,093,177,254.01 as of March 31, 2022, compared to ¥5,997,600,248.38 at the end of December 2021, reflecting an increase of about 1.6%[42] - The total current assets increased to ¥4,154,053,584.91 from ¥4,064,479,153.32, representing a rise of about 2.2% year-over-year[39] - The total liabilities included accounts payable of ¥258,589,397.24, which increased from ¥163,094,814.55, marking a significant rise of about 58.6%[42] - The total liabilities decreased to ¥1,317.09 million in Q1 2022 from ¥1,415.11 million in Q1 2021[44] - The total equity increased to ¥4,776.08 million in Q1 2022 from ¥4,582.49 million in Q1 2021[44] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 47,555[16] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, accounting for 43.03% of total shares[16] - The second largest shareholder, Central Huijin Asset Management Co., Ltd., holds 15,551,120 shares, representing 2.47% of total shares[16] - The company repurchased 566,042 shares, reducing the total outstanding shares to 629,433,958[7] - The company has no pledged, marked, or frozen shares among the top ten shareholders[16] - The company has no related party or concerted action relationships with the top ten shareholders[19] Investment and Financial Products - The company has a total of 675,000 RMB in overdue principal from entrusted loans, with legal proceedings initiated to recover the amount[21] - The company has completed the granting of 510,000 restricted stocks under the 2021 stock incentive plan to 17 incentive objects[22] - The company has entrusted a total of 50 million RMB in non-principal guaranteed floating income financial products with an annualized return rate of 4.32%[25] - The company has also entrusted another 100 million RMB in non-principal guaranteed floating income financial products with an annualized return rate of 4.45%[25] - The company has a total of 100 million RMB in entrusted financial products maturing on June 6, 2022, with a return rate of 3.95%[25] - The company reported a total of ¥2,256,017,632.60 in fixed income products, with a weighted average interest rate of 3.55%[36] - The company has plans for market expansion and new product development, focusing on fixed income products to enhance revenue streams[36] Expenses - Total operating costs for Q1 2022 were ¥721.70 million, up 42.8% from ¥505.25 million in Q1 2021[48] - Research and development expenses for Q1 2022 totaled ¥27.97 million, a 44.7% increase from ¥19.36 million in Q1 2021[48] - Sales expenses in Q1 2022 were ¥353.21 million, up 60.5% from ¥219.75 million in Q1 2021[48] - Cash paid for employee compensation increased to $191.33 million from $146.47 million, reflecting higher personnel costs[54] - Cash paid for taxes rose to $74.98 million from $67.63 million, indicating an increase in tax obligations[54] Investment Income - The company reported a significant increase in investment income, reaching ¥1.19 million in Q1 2022 compared to a loss of ¥0.09 million in Q1 2021[48] - Cash received from investment income was $9.34 million, down from $13.43 million, showing a decline in investment returns[54] - Cash inflow from the recovery of investments was $855.02 million, down from $1,063.00 million, indicating a decrease in cash recovery from investments[54]